Coya receives $5M strategic investment from ADDF for COYA 302 FTD trial

Coya Therapeutics, Inc.

ADDF purchased 603,136 shares at $8.29/share for $5M gross proceeds in private placement.
Funds will support COYA 302 development for frontotemporal dementia (FTD) Phase 2 trial.
ADDF, focused on Alzheimer's and related dementias, backs combination therapy approach.
Registration statement for resale of shares to be filed within 30 days and effective within 75 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.